Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBV-PHICHIT
NCT07258251Phase 4Not yet recruiting
- Sponsor
- Task Force for Global Health
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Task Force for Global Health. Primary endpoints: HBsAg Screening Uptake at 36 months, Linkage to Care at 36 months and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07258251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258251.